novo nordisk's semaglutide failed to slow alzheimer's disease progression Obesity drug fails Ozempic pill fails to slow
Description
Other conditions showing signals Emerging research suggests potential benefit in gout (reduced risk of development in GLP-1 users), osteoarthritis (improved joint outcomes in semaglutide users), and endometriosis (anti-inflammatory mechanisms relevant to endometrial inflammation)
Health and Medicine Division
this result has not been repeated with second-generation sulfonylureas
Clinicians seeking ongoing updates about diabetes therapies can review related coverage at Diabetes in Control, which regularly reports on emerging clinical evidence
